Cargando…
Controlling the SARS-CoV-2 spike glycoprotein conformation
The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581954/ https://www.ncbi.nlm.nih.gov/pubmed/32699321 http://dx.doi.org/10.1038/s41594-020-0479-4 |
_version_ | 1784596885775843328 |
---|---|
author | Henderson, Rory Edwards, Robert J. Mansouri, Katayoun Janowska, Katarzyna Stalls, Victoria Gobeil, Sophie Kopp, Megan Li, Dapeng Parks, Rob Hsu, Allen L. Borgnia, Mario J. Haynes, Barton F. Acharya, Priyamvada |
author_facet | Henderson, Rory Edwards, Robert J. Mansouri, Katayoun Janowska, Katarzyna Stalls, Victoria Gobeil, Sophie Kopp, Megan Li, Dapeng Parks, Rob Hsu, Allen L. Borgnia, Mario J. Haynes, Barton F. Acharya, Priyamvada |
author_sort | Henderson, Rory |
collection | PubMed |
description | The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available β-CoV S-protein structures. Despite overall similarity in domain organization, we found that S-proteins from different β-CoV display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for SARS-CoV-2 S-protein in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs ‘down’ position or adopts ‘up’ state conformations more readily than wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and provide a framework for the development of engineered coronavirus spike proteins for vaccine applications. |
format | Online Article Text |
id | pubmed-8581954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85819542021-11-11 Controlling the SARS-CoV-2 spike glycoprotein conformation Henderson, Rory Edwards, Robert J. Mansouri, Katayoun Janowska, Katarzyna Stalls, Victoria Gobeil, Sophie Kopp, Megan Li, Dapeng Parks, Rob Hsu, Allen L. Borgnia, Mario J. Haynes, Barton F. Acharya, Priyamvada Nat Struct Mol Biol Article The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available β-CoV S-protein structures. Despite overall similarity in domain organization, we found that S-proteins from different β-CoV display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for SARS-CoV-2 S-protein in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs ‘down’ position or adopts ‘up’ state conformations more readily than wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and provide a framework for the development of engineered coronavirus spike proteins for vaccine applications. 2020-07-22 2020-10 /pmc/articles/PMC8581954/ /pubmed/32699321 http://dx.doi.org/10.1038/s41594-020-0479-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Henderson, Rory Edwards, Robert J. Mansouri, Katayoun Janowska, Katarzyna Stalls, Victoria Gobeil, Sophie Kopp, Megan Li, Dapeng Parks, Rob Hsu, Allen L. Borgnia, Mario J. Haynes, Barton F. Acharya, Priyamvada Controlling the SARS-CoV-2 spike glycoprotein conformation |
title | Controlling the SARS-CoV-2 spike glycoprotein conformation |
title_full | Controlling the SARS-CoV-2 spike glycoprotein conformation |
title_fullStr | Controlling the SARS-CoV-2 spike glycoprotein conformation |
title_full_unstemmed | Controlling the SARS-CoV-2 spike glycoprotein conformation |
title_short | Controlling the SARS-CoV-2 spike glycoprotein conformation |
title_sort | controlling the sars-cov-2 spike glycoprotein conformation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581954/ https://www.ncbi.nlm.nih.gov/pubmed/32699321 http://dx.doi.org/10.1038/s41594-020-0479-4 |
work_keys_str_mv | AT hendersonrory controllingthesarscov2spikeglycoproteinconformation AT edwardsrobertj controllingthesarscov2spikeglycoproteinconformation AT mansourikatayoun controllingthesarscov2spikeglycoproteinconformation AT janowskakatarzyna controllingthesarscov2spikeglycoproteinconformation AT stallsvictoria controllingthesarscov2spikeglycoproteinconformation AT gobeilsophie controllingthesarscov2spikeglycoproteinconformation AT koppmegan controllingthesarscov2spikeglycoproteinconformation AT lidapeng controllingthesarscov2spikeglycoproteinconformation AT parksrob controllingthesarscov2spikeglycoproteinconformation AT hsuallenl controllingthesarscov2spikeglycoproteinconformation AT borgniamarioj controllingthesarscov2spikeglycoproteinconformation AT haynesbartonf controllingthesarscov2spikeglycoproteinconformation AT acharyapriyamvada controllingthesarscov2spikeglycoproteinconformation |